JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

JP Morgan kept an underweight rating on GSK with a June 2027 price target of £17, saying the stock sits 5% to 10% below consensus on core earnings from 2027 and that upside depends on pipeline success and new launch execution. Analyst Zain Ebrahim made only modest post-Q1 2026 forecast changes, with FX-driven sales adjustments of 0% to 1% across 2026-2031 and 1% to 2% upgrades to core operating profit estimates. The note is mildly negative for sentiment but appears more likely to affect positioning than drive a major immediate price move.

Analysis

The important read-through is not the modest forecast tweak, but the duration of the skepticism: the market is being told that the earnings inflection is still a 2027+ story, which means any near-term multiple support from quarterly beats is likely capped. For GSK, that creates a classic “good pipeline, bad stock” setup where execution risk on launches becomes the dominant variable versus the headline R&D narrative. In that regime, the shares are likely to trade more like a self-funded launch platform than a defensive healthcare compounder.

Second-order, the risk is that incremental FX help can mask underlying commercial fragility without changing the end-state earnings ceiling. If core operating profit is only getting a low-single-digit lift while consensus remains several percent above internal numbers from 2027, the market can continue to de-rate forward estimates even on seemingly positive print outs. That also raises the bar for competitors with cleaner launch cadence or less binary pipeline dependence to capture relative multiple premium.

Catalysts are asymmetrical over the next 6-18 months: any launch slip, reimbursement delay, or weaker-than-expected uptake would likely be punished immediately because the stock is being valued on an execution bridge that has not yet been built. Conversely, to overturn the negative setup, GSK needs not just approved products but evidence of rapid prescription adoption and durable gross-to-net economics. Absent that, the name remains vulnerable to estimate cuts and range-bound underperformance versus large-cap pharma peers.

The contrarian view is that the market may already be discounting a lot of the pipeline uncertainty, which creates upside if management can show launch sequencing discipline and operating leverage from the existing portfolio. But the burden of proof is now on commercial execution rather than science, and that distinction matters because it is slower to validate and harder to forecast. In short: this is a stock that can rerate only after data, not before it.

Key Decisions for Investors

• Maintain/establish a tactical short in GSK over the next 1-3 months into any strength; risk/reward favors downside as consensus still appears too high versus internal 2027 earnings framing.
• Pair trade: long LLY or NVO vs short GSK for 6-12 months; prefer names with clearer commercial momentum and less binary launch dependence while GSK remains execution-heavy.
• If already long GSK, hedge with short-dated puts or a collar ahead of the next launch/readout window; the payoff is better on protecting against a 10-15% de-rating than on chasing modest upside.
• Avoid adding to GSK until there is evidence of post-launch prescription traction; use a better entry only after 1-2 quarters of adoption data confirm the earnings bridge is real.
• For relative-value investors, look for peers with improving estimate revisions and lower FX sensitivity; the market is likely to reward visibility over pipeline optionality in the next 2-4 quarters.